

CLAIMS

1. A medicinal composition comprising an insulin resistance-improving drug, and vitamin B₁ or derivative thereof.

2. A medicinal composition claimed in Claim 1, comprising 5 to 300 mg of insulin resistance-improving drug, and 1 to 500 mg of vitamin B₁ or derivative thereof for one unit dose.

3. A medicinal composition as claimed in Claim 1 or Claim 2, wherein the insulin resistance-improving drug has a γ -agonist activity of peroxisome proliferator-activated receptor.

4. A medicinal composition as claimed in any one of Claim 1 to Claim 3, wherein the insulin resistance-improving drug is a thiazolidine-type compound having a γ -agonist activity of peroxisome proliferator-activated receptor.

5. A medicinal composition claimed in Claim 4, being pioglitazone, rosiglitazone or CS-011, or a salt thereof.

6. A medicinal composition as claimed in any one of Claim 1 to Claim 3, wherein the insulin resistance-improving drug is a non-thiazolidine-type compound having a γ -agonist activity of peroxisome proliferator-activated receptor.

7. A medicinal composition for treatment of diabetes mellitus claimed in Claim 6, being TAK-559 or FK-614, or salt thereof.

8. A medicinal composition as claimed in any one of Claim 1 to Claim 7, being used for prevention of a side effect selected

from edema, hear enlargement and anemia.